Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

DMAA vs BRTX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
DMAA
Drugs Made In America Acquisition Corp. Ordinary Shares

Shell Companies

Financial ServicesNASDAQ • US
Market Cap$111M
5Y Perf.+6.3%
BRTX
BioRestorative Therapies, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$2M
5Y Perf.-86.5%

DMAA vs BRTX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
DMAA logoDMAA
BRTX logoBRTX
IndustryShell CompaniesBiotechnology
Market Cap$111M$2M
Revenue (TTM)$0.00$383K
Net Income (TTM)$6M$-13M
Gross Margin79.6%
Operating Margin-37.9%
Total Debt$662.00$0.00
Cash & Equiv.$1K$548K

DMAA vs BRTXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

DMAA
BRTX
StockFeb 25May 26Return
Drugs Made In Ameri… (DMAA)100106.3+6.3%
BioRestorative Ther… (BRTX)10013.5-86.5%

Price return only. Dividends and distributions are not included.

Quick Verdict: DMAA vs BRTX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: DMAA leads in 2 of 3 categories, making it the strongest pick for recent price momentum and sentiment and operational efficiency and capital deployment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
DMAA
Drugs Made In America Acquisition Corp. Ordinary Shares
The Banking Pick

DMAA carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.

  • 6.4% 10Y total return vs BRTX's -100.0%
  • Lower volatility, beta 0.00, current ratio 6.27x
  • Beta 0.00, current ratio 6.27x
Best for: long-term compounding and sleep-well-at-night
BRTX
BioRestorative Therapies, Inc.
The Growth Angle

In this particular matchup, BRTX is outpaced on most metrics by others in the set.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)DMAA logoDMAA+5.0% vs BRTX's -88.7%
Efficiency (ROA)DMAA logoDMAA2.4% ROA vs BRTX's -224.5%

DMAA vs BRTX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

DMAADrugs Made In America Acquisition Corp. Ordinary Shares

Segment breakdown not available.

BRTXBioRestorative Therapies, Inc.
FY 2024
Product
74.8%$300,000
Royalty
25.2%$101,000

DMAA vs BRTX — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLDMAALAGGINGBRTX

Income & Cash Flow (Last 12 Months)

Insufficient data to determine a leader in this category.

BRTX and DMAA operate at a comparable scale, with $383,400 and $0 in trailing revenue.

MetricDMAA logoDMAADrugs Made In Ame…BRTX logoBRTXBioRestorative Th…
RevenueTrailing 12 months$0$383,400
EBITDAEarnings before interest/tax-$726,546-$14M
Net IncomeAfter-tax profit$6M-$13M
Free Cash FlowCash after capex-$414,132-$11M
Gross MarginGross profit ÷ Revenue+79.6%
Operating MarginEBIT ÷ Revenue-37.9%
Net MarginNet income ÷ Revenue-33.0%
FCF MarginFCF ÷ Revenue-28.1%
Rev. Growth (YoY)Latest quarter vs prior year-94.9%
EPS Growth (YoY)Latest quarter vs prior year-153.8%
Insufficient data to determine a leader in this category.

Valuation Metrics

DMAA leads this category, winning 1 of 1 comparable metric.
MetricDMAA logoDMAADrugs Made In Ame…BRTX logoBRTXBioRestorative Th…
Market CapShares × price$111M$2M
Enterprise ValueMkt cap + debt − cash$111M$1M
Trailing P/EPrice ÷ TTM EPS-189.29x-0.18x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple9999.00x
Price / SalesMarket cap ÷ Revenue4.09x
Price / BookPrice ÷ Book value/share0.19x
Price / FCFMarket cap ÷ FCF
DMAA leads this category, winning 1 of 1 comparable metric.

Profitability & Efficiency

Evenly matched — DMAA and BRTX each lead in 2 of 4 comparable metrics.

On the Piotroski fundamental quality scale (0–9), DMAA scores 3/9 vs BRTX's 2/9, reflecting mixed financial health.

MetricDMAA logoDMAADrugs Made In Ame…BRTX logoBRTXBioRestorative Th…
ROE (TTM)Return on equity-5.7%
ROA (TTM)Return on assets+2.4%-2.2%
ROICReturn on invested capital-100.4%
ROCEReturn on capital employed-124.7%
Piotroski ScoreFundamental quality 0–932
Debt / EquityFinancial leverage
Net DebtTotal debt minus cash$661-$547,890
Cash & Equiv.Liquid assets$1,351$547,890
Total DebtShort + long-term debt$662$0
Interest CoverageEBIT ÷ Interest expense
Evenly matched — DMAA and BRTX each lead in 2 of 4 comparable metrics.

Total Returns (Dividends Reinvested)

DMAA leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in DMAA five years ago would be worth $10,643 today (with dividends reinvested), compared to $59 for BRTX. Over the past 12 months, DMAA leads with a +5.0% total return vs BRTX's -88.7%. The 3-year compound annual growth rate (CAGR) favors DMAA at 2.1% vs BRTX's -65.9% — a key indicator of consistent wealth creation.

MetricDMAA logoDMAADrugs Made In Ame…BRTX logoBRTXBioRestorative Th…
YTD ReturnYear-to-date+2.1%-83.1%
1-Year ReturnPast 12 months+5.0%-88.7%
3-Year ReturnCumulative with dividends+6.4%-96.0%
5-Year ReturnCumulative with dividends+6.4%-99.4%
10-Year ReturnCumulative with dividends+6.4%-100.0%
CAGR (3Y)Annualised 3-year return+2.1%-65.9%
DMAA leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

DMAA leads this category, winning 2 of 2 comparable metrics.

DMAA is the less volatile stock with a 0.00 beta — it tends to amplify market swings less than BRTX's 2.11 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DMAA currently trades 100.0% from its 52-week high vs BRTX's 10.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricDMAA logoDMAADrugs Made In Ame…BRTX logoBRTXBioRestorative Th…
Beta (5Y)Sensitivity to S&P 5000.00x2.11x
52-Week HighHighest price in past year$10.60$2.05
52-Week LowLowest price in past year$10.09$0.19
% of 52W HighCurrent price vs 52-week peak+100.0%+10.0%
RSI (14)Momentum oscillator 0–10071.141.9
Avg Volume (50D)Average daily shares traded166K5.4M
DMAA leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.
MetricDMAA logoDMAADrugs Made In Ame…BRTX logoBRTXBioRestorative Th…
Analyst RatingConsensus buy/hold/sell
Price TargetConsensus 12-month target
# AnalystsCovering analysts
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

DMAA leads in 3 of 6 categories — strongest in Valuation Metrics and Total Returns. 1 category is tied.

Best OverallDrugs Made In America Acqui… (DMAA)Leads 3 of 6 categories
Loading custom metrics...

DMAA vs BRTX: Frequently Asked Questions

6 questions · data-driven answers · updated daily

01

Which is the better long-term investment — DMAA or BRTX?

Over the past 5 years, Drugs Made In America Acquisition Corp.

Ordinary Shares (DMAA) delivered a total return of +6. 4%, compared to -99. 4% for BioRestorative Therapies, Inc. (BRTX). Over 10 years, the gap is even starker: DMAA returned +6. 4% versus BRTX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

02

Which is safer — DMAA or BRTX?

By beta (market sensitivity over 5 years), Drugs Made In America Acquisition Corp.

Ordinary Shares (DMAA) is the lower-risk stock at 0. 00β versus BioRestorative Therapies, Inc. 's 2. 11β — meaning BRTX is approximately Infinity% more volatile than DMAA relative to the S&P 500.

03

Which has better profit margins — DMAA or BRTX?

Drugs Made In America Acquisition Corp.

Ordinary Shares (DMAA) is the more profitable company, earning 0. 0% net margin versus -22. 4% for BioRestorative Therapies, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DMAA leads at 0. 0% versus -28. 8% for BRTX. At the gross margin level — before operating expenses — BRTX leads at 93. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

04

Which pays a better dividend — DMAA or BRTX?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

05

Is DMAA or BRTX better for a retirement portfolio?

For long-horizon retirement investors, Drugs Made In America Acquisition Corp.

Ordinary Shares (DMAA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 00)). BioRestorative Therapies, Inc. (BRTX) carries a higher beta of 2. 11 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DMAA: +6. 4%, BRTX: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

06

What are the main differences between DMAA and BRTX?

These companies operate in different sectors (DMAA (Financial Services) and BRTX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: DMAA is a small-cap quality compounder stock; BRTX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

DMAA

Quality Business

  • Sector: Financial Services
  • Market Cap > $100B
Run This Screen
Stocks Like

BRTX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 47%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.